Latest Kidney Cancer News
Kidney Cancer News elsewhere on the Web
A personalized neoantigen vaccine may be effective in patients with clear cell renal cell carcinoma, shared David A. Braun, MD, PhD.
Data from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
Joseph Vento, MD, discusses how WHO updates and molecular profiling are shaping trial design and targeted treatment in non–clear cell RCC.
During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.
Background: Distant metastasis is a key factor contributing to poor prognosis in renal cell carcinoma (RCC). Early prediction of metastasis is ...
Collaborative study investigates the unique immune features of rare cancer type, says Yale's David Braun, MD, PhD.
Naomi B. Haas, MD, discusses safety data from the phase 3 KEYNOTE-564 trial of adjuvant pembrolizumab in patients with clear cell renal cell carcinoma.
This Review discusses the different subtypes of non-clear cell renal cell carcinoma in terms of molecular, genetic and clinicopathological characteristics as well as response to therapy. The authors highlight challenges associated with the rarity and heterogeneity of this subset of tumours and ...
Recent oncology breakthroughs showcase innovative treatments and approvals, enhancing patient outcomes in CLL, RCC, NSCLC, and CRC through targeted therapies and combinations.
Arm D of the trial is assessing the performance of [68Ga]Ga-DPI-4452 in detecting ccRCC in patients with an indeterminate renal mass.
No results found.
Articles from Kidney Cancer UK
No results found.
No results found.